Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
By N. Tang, Huan Bai, Xing Chen, Jiale Gong, Dengju Li, Ziyong Sun. Journal of Thrombosis and Haemostasis, 2020
3,406 citations recorded by the source corpus.
A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is worrying, and the application of heparin in COVID‐19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated.
Subfields: Infectious Diseases, Ophthalmology, Surgery
View Paper: https://www.semanticscholar.org/paper/df102150189397589ea2f68dadc1c9acb3a2750f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Surgery
Citations in the corpus
- COVID-19 and Multiorgan Response (2020, neutral): “66 ”
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, background): “Preliminary results, albeit with small number of events and limited adjustment, may suggest a favorable response from LMWH prophylaxis (82,118).”
- Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy (2020, neutral): “(3) (4) (5) (6) (7) (8) Signs of myocardial injury are present in at least one quarter of severe cases.”
- Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 (2020, neutral): “role of AC in disease management remains unclear (3,4).”
- High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study (2020, methodology): “The JAAM-DIC 2016 score [10] , ISTH overt-DIC score [11] and SIC score [8] were calculated daily until day 7. Scores were considered positive as commonly accepted, if ISTH overt-DIC was 5 points or more, JAAM-DIC score was 4 points or more and if SIC was 4 points or more.”
- COVID-19 update: Covid-19-associated coagulopathy (2020, background): “The same investigators [3] reported in 445 patients that anticoagulant therapy, primarily with low molecular weight heparin (LMWH) administered for 7 days or longer was associated with a lower 28-day morality when administered to patients with a sepsis-induced coagulopathy (SIC) score ≥ 4 or a D-dim”
- Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis (2020, positive): “In line with prior recommendations therefore, it is our position that standardized thromboprophylaxis protocols should be implemented in all COVID-19 patients in the absence of contraindications; to mitigate the risk of developing TE and to reduce the mortality risk associated with concomitant TE an”
- Incidence of venous thromboembolism in hospitalized patients with COVID‐19 (2020, background): “Anticoagulant use at admission 0 (0) 19 (12)”
- Biomarkers associated with COVID-19 disease progression (2020, background): “The number of platelets was reported to be significantly reduced in COVID-19 patients [11,53] and was lower in nonsurvivor patients compared to survivors [54].”